SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis

Roche is in the hot seat as its longtime breast cancer blockbuster Herceptin faces a growing stable of biosimilar challengers. But other drugs in Roche's portfolio are on the rise: Look at Perjeta, which aims to build its case as the add-on drug of choice for HER2-positive breast cancer patients.